Skip to main content
Fig. 3 | BMC Anesthesiology

Fig. 3

From: The beneficial use of ultramicronized palmitoylethanolamide as add-on therapy to Tapentadol in the treatment of low back pain: a pilot study comparing prospective and retrospective observational arms

Fig. 3

Neuropathic component evaluation. Douleur neuropathique 4 questions (DN4) score obtained at baseline, during and after 24 weeks in the group treated with um-PEA as add-on to tapentadol (um-PEA-TP group) or with tapentadol alone (TP group). Data are means ± S.E. The neuropathic component decreases significantly over time in both groups (p < 0.0001). A further, significant improvement over time was found in the um-PEA-TP group compared to the TP-only group (p < 0.0001). Statistical analysis were performed with GLMM

Back to article page

BMC Anesthesiology

ISSN: 1471-2253

Contact us